GlassScriptPhysician profile
Rey Llanes
NPI 1437666492
$2,469.58
in general payments reported to CMS, 2019-2025
20 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $523 · 2022: $339 · 2023: $664 · 2024: $608 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,607.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $1,055.99 | 2021-2025 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $569.51 | 2021-2025 | Relistor |
| Almatica Pharma LLC | $169.87 | 2022-2023 | Loreev Xr, Gralise |
| Redhill Biopharma INC. | $130.72 | 2021 | |
| Depuy Synthes Sales INC. | $79.36 | 2022-2023 | Monovisc, Orthovisc |
| Pacira Therapeutics, INC. | $58.30 | 2021 | |
| Collegium Pharmaceutical, INC. | $54.04 | 2021-2022 | |
| Zimmer Biomet Holdings, INC. | $46.52 | 2022 | |
| Abbvie INC. | $39.90 | 2023-2024 | |
| Virtus Pharmaceuticals LLC | $36.09 | 2021 | |
| Boston Scientific Corporation | $34.04 | 2023 | Wavewriter Alpha Prime 16 |
| Valinor Pharma, LLC | $34.02 | 2024 | Movantik |
| Grt US Holding, INC. | $33.96 | 2022 | |
| Ferring Pharmaceuticals INC. | $25.34 | 2022 | |
| Horizon Therapeutics Plc | $24.93 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $19.92 | 2024 | Zilretta, Iovera |
| Kowa Pharmaceuticals America, INC. | $16.64 | 2022 | |
| Orthofix Medical, INC. | $14.66 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $13.73 | 2024 | |
| Hikma Pharmaceuticals USA | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rey Llanes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.